期刊文献+

分子靶向治疗乳腺癌的疗效研究 被引量:1

下载PDF
导出
摘要 目的:探究分子靶向治疗乳腺癌的应用效果。方法:选取2016年9月—2019年7月到我院就诊的86例乳腺癌者为研究对象,以整群随机化方式分组。对照组给予药物保守治疗,研究组给予分子靶向治疗。观察治疗效果、疾病复发率。结果:对照组总有效率为55.81%(24/43),低于研究组的83.72%(36/43);经为期1年随访观察发现,对照组疾病复发率为32.56%(14/43),高于研究组的9.30%(4/43),差异大(P<0.05)。结论:对乳腺癌行分子靶向治疗,效果显著,能使疾病复发率降低,毒性小,对病情恢复具有重要意义。
作者 陈煜
出处 《北方药学》 2020年第6期62-63,共2页 Journal of North Pharmacy
  • 相关文献

参考文献4

二级参考文献55

  • 1张鉴,李军.肿瘤药物治疗学[M].北京:化学工业出版社,2010.9:87-89.
  • 2WolffAC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013.
  • 3Baselga J, Cort6s J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
  • 4Kaufman B, Mackey JR, Clemens MR, et al. Anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study [J]. J Clin Oncol, 2009, 27(33): 5529-5537.
  • 5Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006, 355(26): 2733-2743.
  • 6Verma S, Miles D, Giannil L, et al. Trastuzumab emtansine for HER-2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
  • 7Perez EA, Romond EH, Suman V J, et al. Four-year follow- up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
  • 8Goldhirsch A,Gelber RD,Piccart-Gebhart M J, et al. 2 yearsversus 1 year of adjuvant trastuzumab for HER-2-positive breast cancer(HERA):an open-label, randomised controlled trial[J]. Lancet, 2013, 382(9897): 1021-1028.
  • 9Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER-2- positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748.
  • 10Piccart-Gebhart M J, Holmes AP, Basega J, et al. First results from the phase lII ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-*L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)[EB/OL]. [2015- 06-20]. http: //rneetinglibrary.asco.org/content/128258-144.

共引文献39

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部